ADC Therapeutics SA
For the period ended May 6, 2024. Filed May 6, 2024.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 6, 2024 · Filed May 6, 2024
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · ZYNLONTA
ZYNLONTA
Achieve commercial brand profitability in 2024
LOTIS-5: Complete enrollment in 2H 2024
LOTIS-7: Part 2 enrollment complete with initial efficacy/safety update in 2H 2024; full/mature data in 1H 2025
Investigator-initiated trial in r/r FL: The study is being expanded to 100 patients in a multicenter clinical trial. Updates are anticipated at medical meetings in 2024/2025.
Investigator-initiated trial in r/r MZL: The study is designed to enroll 50 patients in a multicenter clinical trial. Further updates are anticipated at medical meetings in 2024/2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.